drugset / Trial / NCT04635189
Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the effects of daratumumab and lenalidomide without steroids for treating patients with multiple myeloma.
Timeline
- Start
- 2021-07-27
- Primary completion
- 2026-07-31
- Completion
- 2026-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daratumumab | Monoclonal antibody | 16 mg/kg | Subcutaneous |
| Subject | Daratumumab | Monoclonal antibody | 1800 mg | Subcutaneous |
| Comparator | Dexamethasone | Small molecule | 20 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 25 mg | Oral |